Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Chandan Kumar-Sinha and Arul Chinnaiyan summarize the increasing use of sequencing panels to screen for cancer-associated genes in tumor and germline samples. The authors highlight the increasing appreciation of aberrations in regulatory genes or chromatin-related genes and argue that precision oncology must be considered in the context of adding value to the standard of care, not apart from it.